Perspective: What the FDA’s CAR-T label change means for oncology care and patients
The FDA’s decision to remove class-wide REMS (risk evaluation and mitigation strategies) restrictions for CD19- and BCMA-directed CAR-T therapies marks a turning point—not just in regulation, but in patient access and clinical innovation¹. For the first
